These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 30308299

  • 1. A conveniently synthesized Pt (IV) conjugated alginate nanoparticle with ligand self-shielded property for targeting treatment of hepatic carcinoma.
    Wang X, Chang Z, Nie X, Li Y, Hu Z, Ma J, Wang W, Song T, Zhou P, Wang H, Yuan Z.
    Nanomedicine; 2019 Jan; 15(1):153-163. PubMed ID: 30308299
    [Abstract] [Full Text] [Related]

  • 2. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG, Pan ZY, Zhang DY, Cao Q, Ji LN, Mao ZW.
    ACS Appl Mater Interfaces; 2020 Sep 30; 12(39):43444-43455. PubMed ID: 32883070
    [Abstract] [Full Text] [Related]

  • 3. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H, Lai Q, Wang W, Wu Y, Zhang C, Liu Y, Yuan Z.
    Int J Pharm; 2013 Jul 15; 451(1-2):1-11. PubMed ID: 23618965
    [Abstract] [Full Text] [Related]

  • 4. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
    Wang Y, Liu Y, Liu Y, Zhou W, Wang H, Wan G, Sun D, Zhang N, Wang Y.
    Int J Pharm; 2015 Apr 10; 483(1-2):89-100. PubMed ID: 25681730
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
    Ravera M, Gabano E, Bonzani D, Zanellato I, Arrais A, Cantamessa S, Biggiogera M, Osella D.
    J Inorg Biochem; 2018 Dec 10; 189():185-191. PubMed ID: 30312905
    [Abstract] [Full Text] [Related]

  • 7. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
    Huang X, Li G, Li H, Zhong W, Jiang G, Cai J, Xiong Q, Wu C, Su K, Huang R, Xu S, Liu Z, Wang M, Wang H.
    J Med Chem; 2024 May 23; 67(10):8020-8042. PubMed ID: 38727048
    [Abstract] [Full Text] [Related]

  • 8. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy In Vitro and In Vivo.
    Xiang Y, Huang W, Huang C, Long J, Zhou Y, Liu Y, Tang S, He DX, Tan XW, Wei H, Yu CY.
    Mol Pharm; 2020 Sep 08; 17(9):3223-3235. PubMed ID: 32658485
    [Abstract] [Full Text] [Related]

  • 9. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O, Tang Y, Ke X, Chen Y, Hu D, Tu J, Zhao L, Bourkaib N.
    Int J Pharm; 2015 Jan 30; 478(2):553-68. PubMed ID: 25455765
    [Abstract] [Full Text] [Related]

  • 12. NIR Light and GSH Dual-Responsive Upconversion Nanoparticles Loaded with Multifunctional Platinum(IV) Prodrug and RGD Peptide for Precise Cancer Therapy.
    Liu XM, Zhu ZZ, He XR, Zou YH, Chen Q, Wang XY, Liu HM, Qiao X, Wang X, Xu JY.
    ACS Appl Mater Interfaces; 2024 Aug 07; 16(31):40753-40766. PubMed ID: 39046129
    [Abstract] [Full Text] [Related]

  • 13. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
    Zhang X, Li J, Yan M.
    Drug Dev Ind Pharm; 2016 Oct 05; 42(10):1590-9. PubMed ID: 26942448
    [Abstract] [Full Text] [Related]

  • 16. Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy.
    Ling X, Tu J, Wang J, Shajii A, Kong N, Feng C, Zhang Y, Yu M, Xie T, Bharwani Z, Aljaeid BM, Shi B, Tao W, Farokhzad OC.
    ACS Nano; 2019 Jan 22; 13(1):357-370. PubMed ID: 30485068
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.
    Kostrhunova H, Petruzzella E, Gibson D, Kasparkova J, Brabec V.
    Chemistry; 2019 Apr 05; 25(20):5235-5245. PubMed ID: 30740808
    [Abstract] [Full Text] [Related]

  • 19. Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance.
    Ling X, Chen X, Riddell IA, Tao W, Wang J, Hollett G, Lippard SJ, Farokhzad OC, Shi J, Wu J.
    Nano Lett; 2018 Jul 11; 18(7):4618-4625. PubMed ID: 29902013
    [Abstract] [Full Text] [Related]

  • 20. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.